KRC-00715
Product Specifications
UNSPSC Description
KRC-00715 is an effective oral c-Met inhibitor with an IC50 of 9.0 nM, demonstrating high selectivity in gastric cancer cells. KRC-00715 specifically inhibits the growth of c-Met-highly expressed cell lines by inducing G1/S phase arrest, leading to a reduction in downstream signaling pathways, including Akt and Erk, as well as c-Met activity. KRC-00715, in the gastric cancer cell line Hs746, is characterized by an IC50 of 39 nM, and it selectively inhibits the proliferation of c-Met-highly expressed cell lines. KRC-00715 reduces tumor size in Hs746T xenograft mouse models[1].
Target Antigen
c-Met/HGFR
Type
Reference compound
Related Pathways
Protein Tyrosine Kinase/RTK
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/krc-00715.html
Smiles
FC(F)(F)C1=C(OCCN2CCOCC2)C=CC(C3=NC(N(CC4OC(C=CC=N5)=C5NC4)N=N6)=C6N=C3)=C1
Molecular Weight
542.51
References & Citations
[1]Chi Hoon Park, et al. Novel c-Met inhibitor suppresses the growth of c-Met-addicted gastric cancer cells.BMC Cancer. 2016 Jan 22:16:35.
Shipping Conditions
Room temperature
Product Datasheet
http://file.medchemexpress.com/batch_PDF/HY-164411/KRC-00715-DataSheet-MedChemExpress.pdf
Product MSDS
http://file.medchemexpress.com/batch_PDF/HY-164411/
Clinical Information
No Development Reported
CAS Number
2079853-72-6
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
31135-05161 5x 30 µg
Human Carboxypeptidase E (CPE) AssayLite™ Antibody (APC Conjugate)
Ask
View Details